Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/Pfizer) vaccine.Methods: Totally 10735 adult volunteers that received at least one dose of BioNTech/Pfizer or triple doses of CoronaVac participated in this cross-sectional-online survey between 1 and 10 September 2021. The information was collected covering a 5-month period from April 2021 to September 2021. Information about people who were vaccinated with only single and double dose CoronaVac were not included in this study. Results: At least one side effect after single and double dose of BioNTech/Pfizer and triple doses of CoronaVac were observed in 42.1％, 42.5％ and 10.9％, respectively. The most common side effects were shoulder/arm pain, weakness/fatigue, muscle/joint pain and headache. The side effects were the most frequent in single BioNTech/Pfizer, while it was the least in triple CoronaVac. The rate of positive PCR tests before vaccination was 17.6％, and decreased to 3.0％ after vaccination. The rates of positive SARS CoV-2-PCR were 18.8％, 3.5％, 3.1％, 0.5％ and 4.6％ in single BioNTech/Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. While 1.8％ of PCR positive COVID-19 cases needed intensive unit care in the pre-vaccination period, intensive care unit was required in 0％, 1.5％, 2.4％, 0％ and 4.2％ after single BioNTech/Pfizer, double BioNTech/Pfizer, double CoronaVac+single BioNTech/Pfizer, double CoronaVac+double BioNTech/Pfizer and triple CoronaVac, respectively. Reinfection rate after vaccination was 0.4％. Conclusions: The rarity of COVID-19 infection after vaccination suggests that efficacy of vaccines is maintained. On the other hand, the data underscore the critical importance of continued public health mitigation.

Oya Baydar Toprak;Sennur Ozen;Berker Ozturk;Burcu Ozturk;Ebru Ozturk;Mehmet Kitapci;Nurdan Kokturk

Chest Diseases Department,Faculty of Medicine,Cukurova University,Adana,Turkey;Department of Pulmonary Medicine,Delta Hospital,Istanbul,Turkey;Chest Diseases Department,Aksaray Training and Research Hospital,Aksaray,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Gazi University,Ankara,Turkey;Department of Biostatistics,Hacettepe University,Ankara,Turkey;Department of Nuclear Medicine,Integra Medical Imaging Center,Ankara,Turkey

亚太热带医药杂志（英文版）

[1]Oya Baydar Toprak;Sennur Ozen;Berker Ozturk;Burcu Ozturk;Ebru Ozturk;Mehmet Kitapci;Nurdan Kokturk-.SARS-CoV-2 infection rates after different vaccination schemes: An online survey in Turkey)[J].亚太热带医药杂志（英文版）,2022(04):171-178

CoronaVac+single,CoronaVac+double,Reinfection

SARS,CoV,rates,after,different,vaccination,schemes,An,online,survey,Turkey,Objective,identify,effects,various,nationwide,protocols,evolution,new,infections,among,adult,population,evaluate,safety,BioNTech,Pfizer,Methods,Totally,volunteers,that,received,least,one,triple,doses,participated,this,cross,sectional,between,September,information,was,collected,covering,month,period,from,April,Information,about,people,who,were,vaccinated,only,not,included,study,Results,At,side,observed,respectively,most,common,shoulder,arm,pain,weakness,fatigue,muscle,joint,headache,frequent,while,positive,tests,before,decreased,While,cases,needed,intensive,unit,care,pre,required,Conclusions,rarity,suggests,efficacy,vaccines,maintained,On,other,hand,data,underscore,critical,importance,continued,public,health,mitigation

0.405833